Renal Cancer - Results from #2720

Axitinib as a third or further line of treatment in renal cancer: a single institution experience. June 10, 2020

[Durable Response after Discontinuation Due to Immune-Related Adverse Events in a Patient with Metastatic Clear Cell Renal Cell Carcinoma : A Case Report]. June 10, 2020

Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. June 9, 2020

Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. June 9, 2020

Extracellular Vesicles Enriched in hsa-miR-301a-3p and hsa-miR-1293 Dynamics in Clear Cell Renal Cell Carcinoma Patients: Potential Biomarkers of Metastatic Disease. June 8, 2020

Predicting tumor-specific survival in patients with spinal metastatic renal cell carcinoma: which scoring system is most accurate? June 8, 2020

Imaging Mass Spectrometry is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study. June 5, 2020

First cases of combined full robotic partial nephrectomy and colorectal resections: results and new perspectives. June 5, 2020

The SLC Family Are Candidate Diagnostic and Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma. June 5, 2020

Metastasectomy in patients with renal cell carcinoma: when and how? June 4, 2020

Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. June 4, 2020

Expression and clinical value of SALL4 in renal cell carcinomas. June 4, 2020

Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of Renal Cell Carcinoma through regulating cMet pathway. June 4, 2020

Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma. June 3, 2020

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. June 3, 2020

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. June 2, 2020

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. June 2, 2020

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. June 1, 2020

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial May 29, 2020

Comprehensive analysis of the HOXA gene family identifies HOXA13 as a novel oncogenic gene in kidney renal clear cell carcinoma. May 29, 2020

Page 137 of 456